[Evidences and the taking measurements against G-I tract adverse events in amino bisphosphonate].
Amino bisphosphonate (A-BP) is a potent inhibitor of bone resorption through inhibition of mevalonate pathway resulting in increase apoptosis of osteoclast. It is expected that the same metabolic effects of this compound may contribute on the cell damage at G-I tract. Although the some endoscopical studies indicated that alendronate administration significantly associated gastric ulcer or erosion, the data were inconsistent between the studies. Furthermore, recent analysis revealed that A-BP did not increase in adverse events in G-I tract from the reviews of the mega-trials of alendronate and risedronate. Post-marketing surveillance also indicated that amino A-BP did not increase in G-I adverse event (AE) at G-I tract, but physicians have to pay attention about G-I AE after A-BP treatment in the individual patients.